Brought to you by 
Anokion closes CHF33mm Series A round
30 May 2014
Executive Summary
Novartis Venture Funds, Novo Ventures, and Versant Ventures co-led a CHF33mm ($37.5mm) Series A round for Anokion SA (therapies for immune diseases and allergies), and all take seats on the company’s board. Additional undisclosed private investors also participated.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Anokion closes CHF33mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice